rs3787345 — PTPN1 PTPN1 LD Block Co-Variant

The PTP1B Insulin Brake — PTPN1 rs3787345

PTP1B — the protein encoded by PTPN1 — functions as one of the most precisely validated negative regulators of insulin signaling in the human body. When insulin binds its receptor and triggers the tyrosine kinase cascade that drives glucose uptake into muscle and fat cells, PTP1B dephosphorylates the activated insulin receptor¹¹ dephosphorylates the activated insulin receptor
removes phosphate groups from tyrosine residues on the insulin receptor kinase domain, directly terminating downstream glucose-uptake signaling and its immediate substrates, ending each insulin pulse. In animal models, complete deletion of PTP1B²² complete deletion of PTP1B
PTP1B knockout mice remain lean on high-fat diets, show insulin hypersensitivity, and resist diet-induced obesity — providing proof-of-concept that PTP1B expression level is a key determinant of whole-body insulin sensitivity produces profound insulin hypersensitivity and resistance to obesity — establishing PTPN1 as both a drug target and a genetic risk locus for type 2 diabetes and metabolic syndrome.

rs3787345 is an intronic variant at GRCh38 chr20:50568886, situated within the ~100-kb PTPN1 linkage disequilibrium block³³ ~100-kb PTPN1 linkage disequilibrium block
A genomic region where recombination is rare, so all variants within it tend to be inherited together as a fixed haplotype package; every PTPN1 variant associated with insulin resistance and T2D falls within this same block that has been the subject of repeated association studies across European, Hispanic, and Asian cohorts. The variant itself does not alter the PTP1B amino acid sequence; its clinical significance comes from co-segregation with the risk haplotype across this regulatory block.

The Mechanism

The functional driver of this haplotype block is not rs3787345 itself but a functional insertion in the PTPN1 3'-UTR⁴⁴ functional insertion in the PTPN1 3'-UTR
A variant in the untranslated tail of the PTPN1 mRNA that stabilizes the transcript in skeletal muscle, increasing the amount of PTP1B protein produced per transcription event; this was identified by Bento et al. 2004 as the likely causal mechanism within the LD block that stabilizes PTPN1 mRNA in skeletal muscle, raising PTP1B protein levels. Higher PTP1B means each insulin pulse is terminated faster — the kinase window is shorter, less glucose transporter (GLUT4) is translocated to the muscle cell surface, and more circulating insulin is required to achieve the same glucose uptake. In the liver, PTP1B-impaired insulin signaling reduces LDL receptor recycling and increases VLDL assembly, connecting this locus to dyslipidemia independent of adiposity.

rs3787345 sits between rs941798 (chr20:50546698) and rs6020611 (chr20:50578070), two other well-characterized tag SNPs for this same haplotype block. All three variants — rs941798, rs3787345, and rs6020611 — carry the same biological message: minor allele carriage marks the risk haplotype with elevated PTP1B expression.

The Evidence

The haplotype block containing rs3787345 was systematically characterized by Bento et al. 2004⁵⁵ Bento et al. 2004
Bento JL et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes. 2004 Nov;53(11):3007-12, who genotyped 23 noncoding PTPN1 SNPs across 161 kb in Caucasian cohorts and found that all associated variants clustered in a single ~100-kb block with OR ~1.3 for type 2 diabetes and a population-attributable risk of 17–20%. Importantly, the functional mechanism — mRNA stabilization via a 3'-UTR variant — was directly demonstrated, distinguishing this from purely statistical associations.

Palmer et al. 2004⁶⁶ Palmer et al. 2004
Palmer ND et al. Association of PTPN1 gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the IRAS Family Study. Diabetes. 2004 Nov;53(11):3013-9 replicated these findings in 811 Hispanic Americans, showing that all 20 common PTPN1 LD-block SNPs were significantly associated with the insulin sensitivity index (p=0.003) and fasting glucose (p<0.001), extending the signal beyond European populations.

rs3787345 was included in the 14-SNP PTPN1 panel examined by Cheyssac et al. 2006⁷⁷ Cheyssac et al. 2006
Cheyssac C et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet. 2006;7:44, which studied 1,227 T2D cases and 1,047 controls in a French cohort. Haplotype analysis identified the CACG haplotype — incorporating multiple LD-block SNPs including rs3787345 — with marginal association with T2D (unadjusted p=0.02), while rs941798 and rs2426159 showed the most consistent individual associations with fasting insulin, HOMA-B, and lipid markers in normoglycemic controls.

The lipid connection was established by Bauer et al. 2010⁸⁸ Bauer et al. 2010
Bauer F et al. PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol. Eur J Cardiovasc Prev Rehabil. 2010;17(1):28-34, who found that minor allele carriers of closely co-segregating PTPN1 tag SNPs in this same block showed elevated LDL and total cholesterol specifically in lean men (BMI <26 kg/m²; p<0.05) — a BMI-stratified finding consistent with PTP1B-driven insulin resistance elevating cholesterol through direct hepatic mechanisms even in the absence of obesity.

Evidence level is moderate: the T2D signal for this entire LD block is replicated and mechanistically grounded, but the specific individual contribution of rs3787345 — as opposed to its co-varying block companions — has not been isolated at the genome-wide significance level. The signal is strongest at the haplotype level.

Practical Actions

Carrying the C allele at rs3787345 — particularly the CC genotype — marks the PTPN1 risk haplotype that confers chronically elevated PTP1B activity. The most actionable implications are metabolic monitoring and lifestyle choices that offset PTP1B-mediated insulin resistance.

Fasting insulin, HOMA-IR, and fasting LDL are the most informative biomarkers for this haplotype: PTP1B-driven insulin resistance can be present at normal body weight, so these labs add information beyond BMI. Resistance training and aerobic exercise directly downregulate PTP1B expression in skeletal muscle, providing a partially specific countermeasure. Reducing dietary saturated fat below 10% of calories limits hepatic LDL production through the PTP1B-impaired insulin signaling pathway.

Interactions

rs3787345 is in strong LD with rs941798, rs6020611, rs3787348, and rs914458 — all members of the same PTPN1 100-kb risk haplotype block. Carriers of the C allele at rs3787345 are likely co-carriers of the risk alleles at these other loci. If multiple PTPN1 tag SNPs are genotyped, the combination provides stronger haplotype resolution than any single variant alone. At the pathway level, PTPN1 interacts with the insulin receptor (INSR), IRS1, and PIK3R1 — downstream components of the insulin signaling cascade whose variants can compound PTP1B-driven impairment.